Alzheimer's Expansion FDA approvals for TAUKLARIFY and brain-imaging radiopharmaceuticals position Lantheus at the forefront of neurology imaging, creating cross-sell opportunities to oncology and cardiology teams seeking multi-modality diagnostic solutions.

Radiopharma Growth As a leading radiopharmaceutical-focused company with a 70-year track record and recent regulatory wins, Lantheus presents a compelling case for strategic partnerships and channel expansion with hospitals, academic centers, and imaging networks seeking advanced PET tracers.

Strategic Sales Targets Recent investor activity and potential Curium acquisition discussions may influence consolidation dynamics; this suggests urgency to engage on value-based pricing, contingent milestones, and bundled radiopharma offerings before any deal closes.

Global Footprint Headquartered in the US with multiple international offices enables regional market penetration strategies, including Europe and Canada, leveraging established regulatory approvals and local alignment for faster adoption of new radiotracers.

Product Portfolio Leverage TAUKLARIFY and other imaging agents provide opportunities to cross-sell to neurology, oncology, and cardiology care pathways, particularly in centers building integrated PET imaging programs and longitudinal disease monitoring.